Related Experiment Video
Updated: Aug 20, 2025
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
Published on: February 24, 2023
Approaches for development of LAG-3 inhibitors and the promise they hold as anticancer agents
Martin Perez-Santos1, Maricruz Anaya-Ruiz2, Luis Villafaña-Diaz3
1Dirección de Innovación y Transferencia de Conocimiento, Benemérita Universidad Autónoma de Puebla, Puebla CP, México.
Introduction:
LAG-3 is considered to be the third point of immunological control in relation to clinical trials that address cancer treatment, only behind PD-1 and CTLA-4, due to its role as a suppressor of the immune response and enhancer of differentiation of Treg cells.
Areas Covered:
The authors focus on emphasizing the strategy of development of LAG-3 inhibitors to develop anticancer therapeutics, especially from the perspective of designing new monoclonal and bispecific antibodies against LAG-3. This article also covers details of patents and clinical trials of LAG-3 inhibitors reported in the literature. In addition, we highlight as future research challenges the design and development of peptides and small molecules as inhibitors of LAG-3 function.
Expert Opinion:
Three approaches have been used for the development of LAG-3 inhibitors, and they include inhibitory LAG-3 binding peptides and antagonist monoclonal and multispecific antibodies. These approaches include more than 100 clinical trials of 21 molecules that bind to LAG-3 and block its binding to MHC II. However, these approaches do not cover the design and development of peptides and small molecules that could inhibit the function of LAG-3, for which it is necessary to develop new alternatives that cover this gap.
Insights
The study explores Lymphocyte-activation gene 3 (LAG-3) inhibitors for cancer treatment, focusing on antibody-based therapies and future development of peptides and small molecules to enhance immune response against tumors.
Area of Science:
- Immunology
- Oncology
- Drug Development
Background:
- Lymphocyte-activation gene 3 (LAG-3) is a key immune checkpoint, functioning similarly to PD-1 and CTLA-4 in cancer.
- LAG-3 suppresses immune responses and promotes regulatory T cell differentiation, making it a target for cancer therapeutics.
Purpose of the Study:
- To review the development strategies for LAG-3 inhibitors as anticancer therapeutics.
- To analyze current patents and clinical trials involving LAG-3 inhibitors.
- To identify future research challenges in developing novel LAG-3 inhibitors.
Main Methods:
- Review of literature on LAG-3 inhibitors, including patents and clinical trials.
- Analysis of existing therapeutic approaches (monoclonal antibodies, bispecific antibodies).
- Identification of research gaps in peptide and small molecule inhibitor development.
Main Results:
- Over 100 clinical trials involving 21 molecules targeting LAG-3 and its interaction with MHC II have been reported.
- Current strategies primarily focus on blocking LAG-3 binding via antibodies.
- A gap exists in the development of peptides and small molecules that inhibit LAG-3 function.
Conclusions:
- Antibody-based inhibitors represent a significant advancement in LAG-3 targeted cancer therapy.
- Further research is needed to develop peptide and small molecule inhibitors to fully exploit LAG-3's therapeutic potential.
- Addressing these gaps could lead to more effective cancer treatments.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:27Tumor Immunotherapy